From strategic collaborations to partnerships
Our aim is to accelerate work and drive impact.
We look for partners aiming to do the same.
Business development
Kyowa Kirin North America was shaped by business development deals, including global licensing, M&A, and joint ventures of all sizes. The focus has always been on driving the best results for patients, with positive outcomes for everyone involved. We believe the more we can help each other, the more and faster we can help others.
We follow a high-touch alliance approach that we believe helps ensure that both partners can evaluate progress and optimize business results, together.
We seek collaborations in our three areas of focus: rare diseases, hematologic cancers and diseases, and bone and mineral diseases. We also are seeking to advance our work in advanced therapeutic antibodies and hematopoietic stem cell gene therapies.
To start a dialogue, please email busdev.na@kyowakirin.com
Open Innovation
Through our Open Innovation program, we are looking to share ideas, technology, and resources to drive breakthroughs that can change lives.
We welcome partnerships with industry, startups, biotechs, universities, and researchers. We embrace connections with those with a similar mindset and willingness to focus on the potential.
We are actively seeking collaborations and partnerships to advance cutting-edge research in the following areas:
- Cell engineering and synthetic biology
- Gene editing and gene writing/replacement technologies
- Innovative approaches in viral and non-viral vectors and delivery vehicles
- Advanced next-generation CAR/TCR constructs
- Novel innovations and applications across all immune cell lineages
- Allogeneic cell therapy platforms
- Novel (heme-)oncology targets for Cell and Gene Therapy (CGT) approaches
- Expertise in preclinical disease models in particular in hematology and rare conditions with translational relevance
We want to foster long-term relationships with biotech and pharma companies as well as leading academic institutions. Potential collaborative models include:
- Collaborative or sponsored research projects
- Licensing opportunities for promising technologies
- Engagement with key opinion leaders in the field
We believe that combining Kyowa Kirin's strong track record of collaborative drug development successes with our partners’ innovative research will lead to breakthrough therapies for patients with unmet medical needs and deliver life-changing results to the community.
Send your interest area to: kkna.oi.8x@kyowakirin.com
Technology licensing
Our teams have developed antibody technology and expertise that can benefit others. To facilitate that sharing of knowledge, we license our technology to other industry partners with promising drug candidates through BioWa, the exclusive worldwide licensor of our POTELLIGENT® technology.
This antibody technology:
- Dramatically enhances the potency and efficacy of antibodies. Clinical results with Potelligent®- enhanced antibodies are expected to show higher efficacy in human patients when compared with antibodies that have not been enhanced.
- Increases Fc receptor binding – overcomes the problem of low clinical responses due to genetic differences in the Fc receptor.
- Lowers the effective therapeutic dose of your antibodies – the potential to deliver much more with much less.
- Creates antibodies that are expected to be proven safe and well tolerated, with no immunogenic concerns.
- Requires no change in your current manufacturing process – BioWa’s proprietary technology works seamlessly with the systems and processes you already have in place.
- Reduces costs of goods (COGs).
To learn more about POTELLIGENT®, Visit BioWa
or complete this form to reach one of our licensing managers.
Investigator-Initiated
Studies
As part of our commitment to delivering innovative therapies to patients worldwide, Kyowa Kirin believes in the need to support independent research conducted by qualified independent investigators – or Investigator–Initiated Studies.
The scientific evidence generated through these independent research initiatives helps deepen our understanding of the benefit/risk profiles of our products, as well as allows us to explore new opportunities to address unmet medical needs in our therapeutic areas of interest.
Investigator-Initiated Studies
Patient advocacy groups
Advocacy organizations can play a vital role in the lives of patients and families, serving as a source of unbiased education, advice, understanding, and treatment support. That’s why we are proud to partner with more than 24 organizations in North America that provide services in areas aligned with our portfolio.
We work with patients and community leaders in a number of ways:
- Conducting research into patient and caregiver needs.
- Improving the design of clinical trials.
- Investing in disease awareness and education campaigns.
- Advancing patient-friendly policies for affordable coverage and care.
- Supporting meetings and educational events in our therapeutic areas.
Advocacy organizations who are interested in meeting with Kyowa Kirin North America to discuss opportunities for collaboration may reach out to Public Affairs publicaffairs.na@kyowakirin.com or submit grant requests for consideration at grantrequests.na@kyowakirin.com